Incidence of major hemorrhage after aggressive image-guided liver mass biopsy in the era of individualized medicine

  • James H. Boyum
  • Thomas D. Atwell
  • Darci J. Wall
  • Aaron S. Mansfield
  • Sarah E. Kerr
  • Tina M. Gunderson
  • Kandelaria M. Rumilla
  • Adam J. Weisbrod
  • A. Nicholas Kurup
Article
  • 11 Downloads

Abstract

Purpose

To analyze a large volume of image-guided liver mass biopsies to assess for an increased incidence of major hemorrhage after aggressive liver mass sampling, and to determine if coaxial technique reduces major hemorrhage rate.

Methods

Patients who underwent image-guided liver mass biopsy over a 15-year period (December 7, 2001–September 22, 2016) were retrospectively identified. An aggressive biopsy was defined as a biopsy event in which ≥ 4 core needle passes were performed. Association of major hemorrhage after aggressive liver mass biopsy and other potential risk factors of interest were assessed using logistic regression analysis. For the subset of aggressive biopsies, Fisher’s exact test was used to compare the incidence of major hemorrhage using coaxial versus noncoaxial techniques.

Results

Aggressive biopsies constituted 11.6% of biopsy events (N =579/5011). The incidence of major hemorrhage with <4 passes was 0.4% (N =18/4432) and with ≥4 passes 1.2% (N =6/579). In univariable models, aggressive biopsy was significantly associated with major hemorrhage (OR 3.0, 95% CI 1.16–6.92, p =0.025). After adjusting for gender and platelet count, the association was not significant at the p =0.05 level (OR 2.58, 95% CI 0.927–6.24, p =0.067). The rate of major hemorrhage in the coaxial biopsy technique group was 1.4% (N =3/209) compared to 1.1% (N =4/370) in the noncoaxial biopsy technique group, which was not a significant difference (p =0.707).

Conclusions

Although aggressive image-guided liver mass biopsies had an increased incidence of major hemorrhage, the overall risk of bleeding remained low. The benefit of such biopsies will almost certainly outweigh the risk in most patients.

Keywords

Liver Biopsy High-pass Hematoma 

Notes

Compliance with ethical standards

Funding

Funding for data management and analysis was provided by the Mayo Clinic Radiology Research Committee.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Ferreira BI, Hill R, Link W (2015) Special review: caught in the crosshairs: targeted drugs and personalized medicine. Cancer J (Sudbury, Mass) 21(6):441–447.  https://doi.org/10.1097/PPO.0000000000000161 CrossRefGoogle Scholar
  2. 2.
    Conley BA, Doroshow JH (2014) Molecular analysis for therapy choice: NCI MATCH. Semin Oncol 41(3):297–299.  https://doi.org/10.1053/j.seminoncol.2014.05.002 CrossRefPubMedGoogle Scholar
  3. 3.
    Marshall D, Laberge JM, Firetag B, Miller T, Kerlan RK (2013) The changing face of percutaneous image-guided biopsy: molecular profiling and genomic analysis in current practice. J Vasc Interv Radiol 24(8):1094–1103.  https://doi.org/10.1016/j.jvir.2013.04.027 CrossRefPubMedGoogle Scholar
  4. 4.
    Tam AL, Lim HJ, Wistuba II, et al. (2016) Image-guided biopsy in the era of personalized cancer care: proceedings from the society of interventional radiology research consensus panel. J Vasc Interv Radiol 27(1):8–19.  https://doi.org/10.1016/j.jvir.2015.10.019 CrossRefPubMedGoogle Scholar
  5. 5.
    McGill DB, Rakela J, Zinsmeister AR, Ott BJ (1990) A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 99(5):1396–1400CrossRefPubMedGoogle Scholar
  6. 6.
    Kohli M, Mayo-Smith W, Zagoria R, Sandrasegaran K (2016) Image-guided intervention in the coagulopathic patient. Abdom Radiol (New York) 41(4):667–676.  https://doi.org/10.1007/s00261-016-0663-5 CrossRefGoogle Scholar
  7. 7.
    Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD (2009) Liver biopsy. Hepatology 49(3):1017–1044.  https://doi.org/10.1002/hep.22742 CrossRefPubMedGoogle Scholar
  8. 8.
    Howlett DC, Drinkwater KJ, Lawrence D, Barter S, Nicholson T (2012) Findings of the UK national audit evaluating image-guided or image-assisted liver biopsy. Part I. Procedural aspects, diagnostic adequacy, and accuracy. Radiology 265(3):819–831.  https://doi.org/10.1148/radiol.12111562 CrossRefPubMedGoogle Scholar
  9. 9.
    McVay PA, Toy PT (1990) Lack of increased bleeding after liver biopsy in patients with mild hemostatic abnormalities. Am J Clin Pathol 94(6):747–753CrossRefPubMedGoogle Scholar
  10. 10.
    O’Connor SD, Taylor AJ, Williams EC, Winter TC (2009) Coagulation concepts update. AJR Am J Roentgenol 193(6):1656–1664.  https://doi.org/10.2214/ajr.08.2191 CrossRefPubMedGoogle Scholar
  11. 11.
    Segal JB, Dzik WH (2005) Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 45(9):1413–1425.  https://doi.org/10.1111/j.1537-2995.2005.00546.x CrossRefPubMedGoogle Scholar
  12. 12.
    Kitchin DR, Del Rio AM, Woods M, Ludeman L, Hinshaw JL (2017) Percutaneous liver biopsy and revised coagulation guidelines: a 9-year experience. Abdom Radiol (New York) .  https://doi.org/10.1007/s00261-017-1319-9 Google Scholar
  13. 13.
    Mueller M, Kratzer W, Oeztuerk S, et al. (2012) Percutaneous ultrasonographically guided liver punctures: an analysis of 1961 patients over a period of ten years. BMC Gastroenterol 12:173.  https://doi.org/10.1186/1471-230x-12-173 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Perrault J, McGill DB, Ott BJ, Taylor WF (1978) Liver biopsy: complications in 1000 inpatients and outpatients. Gastroenterology 74(1):103–106PubMedGoogle Scholar
  15. 15.
    Vijayaraghavan GR, Vedantham S, Rangan V, et al. (2015) Effect of needle gauge and lobe laterality on parenchymal liver biopsy outcome: a retrospective analysis. Abdom Imaging 40(5):1223–1229.  https://doi.org/10.1007/s00261-014-0290-y CrossRefPubMedGoogle Scholar
  16. 16.
    Boyum JH, Atwell TD, Schmit GD, et al. (2016) Incidence and risk factors for adverse events related to image-guided liver biopsy. Mayo Clin Proc 91(3):329–335.  https://doi.org/10.1016/j.mayocp.2015.11.015 CrossRefPubMedGoogle Scholar
  17. 17.
    Atwell TD, Smith RL, Hesley GK, et al. (2010) Incidence of bleeding after 15,181 percutaneous biopsies and the role of aspirin. AJR Am J Roentgenol 194(3):784–789.  https://doi.org/10.2214/AJR.08.2122 CrossRefPubMedGoogle Scholar
  18. 18.
    Institute NC (2010) Common terminology criteria for adverse events v4.0. National Cancer Institute. https://ctep.cancer.gov/. Accessed Aug 8 2017
  19. 19.
    Ziv E, Durack JC, Solomon SB (2016) The Importance of Biopsy in the Era of Molecular Medicine. Cancer J (Sudbury, Mass) 22(6):418–422CrossRefGoogle Scholar
  20. 20.
    Tacher V, Le Deley MC, Hollebecque A, et al. (2016) Factors associated with success of image-guided tumour biopsies: results from a prospective molecular triage study (MOSCATO-01). Eur J Cancer 59:79–89.  https://doi.org/10.1016/j.ejca.2016.02.006 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • James H. Boyum
    • 1
  • Thomas D. Atwell
    • 1
  • Darci J. Wall
    • 1
  • Aaron S. Mansfield
    • 2
  • Sarah E. Kerr
    • 3
  • Tina M. Gunderson
    • 4
  • Kandelaria M. Rumilla
    • 3
  • Adam J. Weisbrod
    • 1
  • A. Nicholas Kurup
    • 1
  1. 1.Department of RadiologyMayo ClinicRochesterUSA
  2. 2.Department of Medical OncologyMayo ClinicRochesterUSA
  3. 3.Department of Laboratory Medicine and PathologyMayo ClinicRochesterUSA
  4. 4.Department of Clinical StatisticsMayo ClinicRochesterUSA

Personalised recommendations